Histologic transformation from Waldenström macroglobulinemia (WM) to diffuse large B-cell lymphoma (DLBCL) remains a significant clinical challenge. Although this event occurs rarely, it often leads to a rapid decline in patient health. Fortunately, recent findings suggest that **BTK inhibitor-based therapy** can provide a vital survival benefit for those facing this aggressive progression.

A recent retrospective study analyzed fifteen cases of transformation among WM patients over a ten-year period. Researchers found that most patients presented with stage IV disease at the time of transformation. Furthermore, they noted frequent involvement of extranodal sites, including the central nervous system and bone marrow. Notably, nearly 87% of these cases exhibited the non-germinal center B-cell (non-GCB) DLBCL phenotype, which usually indicates more aggressive behavior.

Improved Outcomes with BTK Inhibitor-based Therapy

Analysis of prognostic factors revealed that patients receiving **BTK inhibitor-based therapy** after transformation experienced significantly longer overall survival. Specifically, the data showed a median overall survival of 26 months. In addition, there was a noticeable trend toward improved survival for patients who used these inhibitors at any point during their treatment course.

Consequently, these findings offer hope for a population that traditionally faces a poor prognosis. Clinicians should consider incorporating Bruton’s tyrosine kinase inhibitors into treatment protocols for transformed WM. Moreover, early detection of transformation remains crucial for initiating these effective interventions promptly. Therefore, regular monitoring of WM patients for signs of aggressive progression is essential for optimizing care.

Frequently Asked Questions

How common is histologic transformation in Waldenström macroglobulinemia?

Histologic transformation from WM to DLBCL is rare, occurring in approximately 1% to 10% of patients. However, it represents an aggressive event that significantly lowers the expected survival rate.

What are the common extranodal sites involved during transformation?

Common extranodal sites include the bone marrow, central nervous system, and gastrointestinal tract. Involvement of immune-privileged sites like the testes or CNS is also frequently observed during this progression.

Does the phenotype of the DLBCL matter in these cases?

Yes, most transformed cases show a non-germinal center B-cell (non-GCB) phenotype. This specific subtype typically carries a more aggressive clinical course compared to the germinal center B-cell subtype.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider for medical concerns. Refer to the latest local and national guidelines for clinical practice.

References

1. Xia Y et al. A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia. Ann Med. 2026 Dec undefined. doi: 10.1080/07853890.2026.2624909. PMID: 41797694.


2. Castillo JJ, et al. Histologic transformation of Waldenström macroglobulinemia: a study of 45 cases. American Journal of Hematology. 2016;91(4):410-415.


3. Durot E, et al. Histologic transformation of Waldenström macroglobulinemia: a retrospective study of 77 patients. Blood. 2017;130(suppl 1):4047.

"